Dr. Seth Wander is a medical oncologist at the Massachusetts General Hospital with a clinical and translational research interest in breast cancer and cancer genomics. Dr. Wander completed his undergraduate degree at Cornell University, where he studied Molecular and Cell Biology and graduated magna cum laude with distinction in research. He pursued his MD and PhD in Cancer Biology at the University of Miami. Dr. Wander completed his internship and residency in internal medicine at the Massachusetts General Hospital and his fellowship training in medical oncology at the Dana-Farber Cancer Institute and the Massachusetts General Hospital Cancer Center. 

Dr. Wander serves as the Director of Translational Research for the Breast Oncology Program, where he leads a multidisciplinary team focused upon leveraging genetic and molecular sequencing results to understand how cancers become resistant to standard therapies in order to develop novel, personalized treatment strategies. Dr. Wander has published more than seventy peer-reviewed manuscripts in the field of precision medicine and continues to present educational sessions and original research nationally and internationally related to drug resistance and the development of personalized therapy for breast cancer. Dr. Wander is an Assistant Professor of Medicine at Harvard Medical School and remains engaged in teaching medical students, residents, and fellows. He was a recipient of the 2017 Dana-Farber Cancer Institute Wong Family Translational Research Award and a 2018 recipient of the Conquer Cancer Foundation/American Society of Clinical Oncology Young Investigator Award. As the Director of Precision Medicine in the Termeer Center for Targeted Therapies, he leads efforts across the MGH Cancer Center to promote novel and innovative research leveraging emerging genetic sequencing technologies to both understand resistance to cancer therapies and inform the design of new clinical trials. Dr. Wander's research has helped to shape our understanding of drug resistance in metastatic breast cancer, and he continues to lead a variety of clinical trials, across all phases of drug development, focused upon developing new, personalized treatment options for patients with breast cancer.